JPWO2020102499A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020102499A5 JPWO2020102499A5 JP2021526394A JP2021526394A JPWO2020102499A5 JP WO2020102499 A5 JPWO2020102499 A5 JP WO2020102499A5 JP 2021526394 A JP2021526394 A JP 2021526394A JP 2021526394 A JP2021526394 A JP 2021526394A JP WO2020102499 A5 JPWO2020102499 A5 JP WO2020102499A5
- Authority
- JP
- Japan
- Prior art keywords
- fusosome
- cell
- cns
- target cell
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 214
- 210000003169 central nervous system Anatomy 0.000 claims description 80
- 108090000623 proteins and genes Proteins 0.000 claims description 70
- 230000001105 regulatory effect Effects 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 210000004498 neuroglial cell Anatomy 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 108020004707 nucleic acids Proteins 0.000 claims description 22
- 102000039446 nucleic acids Human genes 0.000 claims description 22
- 150000007523 nucleic acids Chemical class 0.000 claims description 22
- 210000002569 neuron Anatomy 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 210000001519 tissue Anatomy 0.000 claims description 19
- 208000035475 disorder Diseases 0.000 claims description 17
- 108091070501 miRNA Proteins 0.000 claims description 15
- 239000002679 microRNA Substances 0.000 claims description 15
- 239000000232 Lipid Bilayer Substances 0.000 claims description 14
- 230000009395 genetic defect Effects 0.000 claims description 14
- 239000012212 insulator Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 13
- -1 Dock10 Proteins 0.000 claims description 12
- 210000001130 astrocyte Anatomy 0.000 claims description 12
- 230000002025 microglial effect Effects 0.000 claims description 12
- 210000004248 oligodendroglia Anatomy 0.000 claims description 12
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 230000003308 immunostimulating effect Effects 0.000 claims description 9
- 108091006027 G proteins Proteins 0.000 claims description 8
- 102000030782 GTP binding Human genes 0.000 claims description 8
- 108091000058 GTP-Binding Proteins 0.000 claims description 8
- 208000033868 Lysosomal disease Diseases 0.000 claims description 8
- 101710169105 Minor spike protein Proteins 0.000 claims description 8
- 101710081079 Minor spike protein H Proteins 0.000 claims description 8
- 208000015114 central nervous system disease Diseases 0.000 claims description 8
- 230000001506 immunosuppresive effect Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 claims description 7
- 108091005804 Peptidases Proteins 0.000 claims description 7
- 239000004365 Protease Substances 0.000 claims description 7
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims description 7
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims description 7
- 230000001973 epigenetic effect Effects 0.000 claims description 7
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims description 6
- 210000002987 choroid plexus Anatomy 0.000 claims description 6
- 210000005064 dopaminergic neuron Anatomy 0.000 claims description 6
- 210000001222 gaba-ergic neuron Anatomy 0.000 claims description 6
- 230000000862 serotonergic effect Effects 0.000 claims description 6
- 210000001362 glutamatergic neuron Anatomy 0.000 claims description 5
- 238000013518 transcription Methods 0.000 claims description 5
- 230000035897 transcription Effects 0.000 claims description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 claims description 4
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 claims description 4
- 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 claims description 4
- 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 claims description 4
- 108010058699 Choline O-acetyltransferase Proteins 0.000 claims description 4
- 101150110160 DRD1 gene Proteins 0.000 claims description 4
- 102100031563 Excitatory amino acid transporter 1 Human genes 0.000 claims description 4
- 101150014889 Gad1 gene Proteins 0.000 claims description 4
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 claims description 4
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims description 4
- 102100035902 Glutamate decarboxylase 1 Human genes 0.000 claims description 4
- 102100022373 Homeobox protein DLX-5 Human genes 0.000 claims description 4
- 101000866286 Homo sapiens Excitatory amino acid transporter 1 Proteins 0.000 claims description 4
- 101000901627 Homo sapiens Homeobox protein DLX-5 Proteins 0.000 claims description 4
- 101000598051 Homo sapiens Transmembrane protein 119 Proteins 0.000 claims description 4
- 108091006283 SLC17A7 Proteins 0.000 claims description 4
- 108091006774 SLC18A3 Proteins 0.000 claims description 4
- 102100037029 Transmembrane protein 119 Human genes 0.000 claims description 4
- 102100039452 Vesicular acetylcholine transporter Human genes 0.000 claims description 4
- 102100038039 Vesicular glutamate transporter 1 Human genes 0.000 claims description 4
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 4
- 210000002932 cholinergic neuron Anatomy 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 102100024085 Alpha-aminoadipic semialdehyde dehydrogenase Human genes 0.000 claims description 3
- 208000031277 Amaurotic familial idiocy Diseases 0.000 claims description 3
- 102100032948 Aspartoacylase Human genes 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 108010078286 Ataxins Proteins 0.000 claims description 3
- 102000014461 Ataxins Human genes 0.000 claims description 3
- 102100022549 Beta-hexosaminidase subunit beta Human genes 0.000 claims description 3
- 102100032487 Beta-mannosidase Human genes 0.000 claims description 3
- 108700030955 C9orf72 Proteins 0.000 claims description 3
- 101150014718 C9orf72 gene Proteins 0.000 claims description 3
- 108091005470 CRHR2 Proteins 0.000 claims description 3
- 208000022526 Canavan disease Diseases 0.000 claims description 3
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 3
- 208000001914 Fragile X syndrome Diseases 0.000 claims description 3
- 102100027525 Frataxin, mitochondrial Human genes 0.000 claims description 3
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 3
- 101150103820 Fxn gene Proteins 0.000 claims description 3
- 102100028496 Galactocerebrosidase Human genes 0.000 claims description 3
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims description 3
- 102100029301 Guanine nucleotide exchange factor C9orf72 Human genes 0.000 claims description 3
- 241000035314 Henipavirus Species 0.000 claims description 3
- 101000690235 Homo sapiens Alpha-aminoadipic semialdehyde dehydrogenase Proteins 0.000 claims description 3
- 101000901140 Homo sapiens Arylsulfatase A Proteins 0.000 claims description 3
- 101000797251 Homo sapiens Aspartoacylase Proteins 0.000 claims description 3
- 101001045440 Homo sapiens Beta-hexosaminidase subunit alpha Proteins 0.000 claims description 3
- 101001045433 Homo sapiens Beta-hexosaminidase subunit beta Proteins 0.000 claims description 3
- 101001016707 Homo sapiens Beta-mannosidase Proteins 0.000 claims description 3
- 101000860395 Homo sapiens Galactocerebrosidase Proteins 0.000 claims description 3
- 101001072470 Homo sapiens N-acetylglucosamine-1-phosphotransferase subunits alpha/beta Proteins 0.000 claims description 3
- 101000624947 Homo sapiens Nesprin-1 Proteins 0.000 claims description 3
- 101000836337 Homo sapiens Probable helicase senataxin Proteins 0.000 claims description 3
- 101000828537 Homo sapiens Synaptic functional regulator FMR1 Proteins 0.000 claims description 3
- 101000893741 Homo sapiens Tissue alpha-L-fucosidase Proteins 0.000 claims description 3
- 101000772888 Homo sapiens Ubiquitin-protein ligase E3A Proteins 0.000 claims description 3
- 208000028226 Krabbe disease Diseases 0.000 claims description 3
- 102000003624 MCOLN1 Human genes 0.000 claims description 3
- 101150091161 MCOLN1 gene Proteins 0.000 claims description 3
- 101150083522 MECP2 gene Proteins 0.000 claims description 3
- 102100039124 Methyl-CpG-binding protein 2 Human genes 0.000 claims description 3
- 208000008955 Mucolipidoses Diseases 0.000 claims description 3
- 102100036710 N-acetylglucosamine-1-phosphotransferase subunits alpha/beta Human genes 0.000 claims description 3
- 102100023306 Nesprin-1 Human genes 0.000 claims description 3
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 claims description 3
- 208000036700 Oculomotor apraxia Diseases 0.000 claims description 3
- 102100027178 Probable helicase senataxin Human genes 0.000 claims description 3
- 208000008986 Pyridoxine-dependent epilepsy Diseases 0.000 claims description 3
- 208000006289 Rett Syndrome Diseases 0.000 claims description 3
- 102000005041 SLC6A8 Human genes 0.000 claims description 3
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 3
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 claims description 3
- 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 claims description 3
- 102100023532 Synaptic functional regulator FMR1 Human genes 0.000 claims description 3
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 claims description 3
- 101150014554 TARDBP gene Proteins 0.000 claims description 3
- 208000022292 Tay-Sachs disease Diseases 0.000 claims description 3
- 102100040526 Tissue alpha-L-fucosidase Human genes 0.000 claims description 3
- 108010039203 Tripeptidyl-Peptidase 1 Proteins 0.000 claims description 3
- 102100034197 Tripeptidyl-peptidase 1 Human genes 0.000 claims description 3
- 102100030434 Ubiquitin-protein ligase E3A Human genes 0.000 claims description 3
- 108700005875 X-linked Creatine deficiency Proteins 0.000 claims description 3
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 3
- 108010007169 creatine transporter Proteins 0.000 claims description 3
- 201000002997 creatine transporter deficiency Diseases 0.000 claims description 3
- 201000008049 fucosidosis Diseases 0.000 claims description 3
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 claims description 3
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 claims description 3
- 230000001177 retroviral effect Effects 0.000 claims description 3
- 108091026890 Coding region Proteins 0.000 claims description 2
- 241000893570 Hendra henipavirus Species 0.000 claims description 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 2
- 208000000501 Lipidoses Diseases 0.000 claims description 2
- 206010024585 Lipidosis Diseases 0.000 claims description 2
- 241000712079 Measles morbillivirus Species 0.000 claims description 2
- 108091080995 Mir-9/mir-79 microRNA precursor family Proteins 0.000 claims description 2
- 241000712045 Morbillivirus Species 0.000 claims description 2
- 206010072930 Mucolipidosis type IV Diseases 0.000 claims description 2
- 102100026502 Mucolipin-1 Human genes 0.000 claims description 2
- 241000711408 Murine respirovirus Species 0.000 claims description 2
- 101000930679 Nipah virus Fusion glycoprotein F0 Proteins 0.000 claims description 2
- 241001533467 Rubulavirus Species 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 claims description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 108091056924 miR-124 stem-loop Proteins 0.000 claims description 2
- 108091084619 miR-125b-1 stem-loop Proteins 0.000 claims description 2
- 108091063409 miR-125b-2 stem-loop Proteins 0.000 claims description 2
- 108091050014 miR-125b-3 stem-loop Proteins 0.000 claims description 2
- 108091070038 miR-338 stem-loop Proteins 0.000 claims description 2
- 108091074070 miR-338-3 stem-loop Proteins 0.000 claims description 2
- 108091055145 miR-342 stem-loop Proteins 0.000 claims description 2
- 108091047084 miR-9 stem-loop Proteins 0.000 claims description 2
- 230000030147 nuclear export Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000004481 post-translational protein modification Effects 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 230000037426 transcriptional repression Effects 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 10
- 102100022146 Arylsulfatase A Human genes 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 230000021633 leukocyte mediated immunity Effects 0.000 description 3
- 102100035972 ATPase GET3 Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000526636 Nipah henipavirus Species 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 241001113283 Respirovirus Species 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025075701A JP2025111747A (ja) | 2018-11-14 | 2025-04-30 | Ｃｎｓ送達のためのフソソーム組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862767358P | 2018-11-14 | 2018-11-14 | |
| US62/767,358 | 2018-11-14 | ||
| US201962900064P | 2019-09-13 | 2019-09-13 | |
| US62/900,064 | 2019-09-13 | ||
| PCT/US2019/061424 WO2020102499A2 (en) | 2018-11-14 | 2019-11-14 | Fusosome compositions for cns delivery |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025075701A Division JP2025111747A (ja) | 2018-11-14 | 2025-04-30 | Ｃｎｓ送達のためのフソソーム組成物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022507454A JP2022507454A (ja) | 2022-01-18 |
| JP2022507454A5 JP2022507454A5 (https=) | 2022-11-22 |
| JPWO2020102499A5 true JPWO2020102499A5 (https=) | 2022-11-22 |
| JP7676305B2 JP7676305B2 (ja) | 2025-05-14 |
Family
ID=68808599
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526394A Active JP7676305B2 (ja) | 2018-11-14 | 2019-11-14 | Ｃｎｓ送達のためのフソソーム組成物 |
| JP2025075701A Pending JP2025111747A (ja) | 2018-11-14 | 2025-04-30 | Ｃｎｓ送達のためのフソソーム組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025075701A Pending JP2025111747A (ja) | 2018-11-14 | 2025-04-30 | Ｃｎｓ送達のためのフソソーム組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220008557A1 (https=) |
| EP (1) | EP3880179A2 (https=) |
| JP (2) | JP7676305B2 (https=) |
| KR (1) | KR20210133948A (https=) |
| CN (1) | CN113613633A (https=) |
| AU (1) | AU2019378881A1 (https=) |
| CA (1) | CA3120082A1 (https=) |
| IL (1) | IL283179A (https=) |
| SG (1) | SG11202105079QA (https=) |
| WO (1) | WO2020102499A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| US11624061B2 (en) | 2017-04-28 | 2023-04-11 | Agrospheres, Inc. | Compositions and methods for enzyme immobilization |
| AU2018256925B2 (en) | 2017-04-28 | 2024-11-21 | Agrospheres, Inc. | Compositions and methods for the encapsulation and scalable delivery of agrochemicals |
| BR112020005803A2 (pt) | 2017-09-25 | 2020-12-01 | Agrospheres, Inc. | composições e métodos para produção e administração moduláveis de produtos biológicos |
| EP3820509A1 (en) | 2018-07-09 | 2021-05-19 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| US12496274B2 (en) | 2018-11-14 | 2025-12-16 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for compartment-specific cargo delivery |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| JP7657726B2 (ja) | 2019-03-19 | 2025-04-07 | ザ ブロード インスティテュート，インコーポレーテッド | 編集ヌクレオチド配列を編集するための方法および組成物 |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| WO2020252455A1 (en) | 2019-06-13 | 2020-12-17 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| AU2020341454A1 (en) | 2019-09-03 | 2022-03-10 | Sana Biotechnology, Inc. | CD24-associated particles and related methods and uses thereof |
| JP2023521663A (ja) * | 2020-03-31 | 2023-05-25 | サナ バイオテクノロジー，インコーポレイテッド | 標的化脂質粒子及び組成物ならびにその使用 |
| EP4185600A4 (en) | 2020-07-24 | 2024-12-04 | The General Hospital Corporation | Enhanced virus-like particles and methods of use thereof for delivery to cells |
| EP4274901A1 (en) | 2021-01-11 | 2023-11-15 | Sana Biotechnology, Inc. | Use of cd8-targeted viral vectors |
| IL307544A (en) | 2021-04-08 | 2023-12-01 | Sana Biotechnology Inc | Cd8-specific antibody constructs and compositions thereof |
| AU2022280957A1 (en) | 2021-05-28 | 2023-11-30 | Sana Biotechnology, Inc. | Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses |
| WO2023015217A1 (en) | 2021-08-04 | 2023-02-09 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| WO2023039242A2 (en) * | 2021-09-13 | 2023-03-16 | Achelois Biopharma, Inc. | Multivalent interferon particles compositions and methods of use |
| EP4448775A1 (en) | 2021-12-17 | 2024-10-23 | Sana Biotechnology, Inc. | Modified paramyxoviridae attachment glycoproteins |
| US20250059239A1 (en) | 2021-12-17 | 2025-02-20 | Sana Biotechnology, Inc. | Modified paramyxoviridae fusion glycoproteins |
| EP4472646A1 (en) | 2022-02-01 | 2024-12-11 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| US20250144235A1 (en) | 2022-02-02 | 2025-05-08 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| US20260055146A1 (en) | 2022-08-24 | 2026-02-26 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| US20260098062A1 (en) | 2022-09-21 | 2026-04-09 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| JP2025532963A (ja) * | 2022-09-30 | 2025-10-03 | ヴェサイジェン，インコーポレーテッド | 眼の細胞および組織への治療用薬剤のａｒｒｄｃ１介在性の微小小胞体に基づく送達 |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| EP4698665A1 (en) | 2023-04-18 | 2026-02-25 | Sana Biotechnology, Inc. | Engineered protein g fusogens and related lipid particles and methods thereof |
| EP4698666A1 (en) | 2023-04-18 | 2026-02-25 | Sana Biotechnology, Inc. | Universal protein g fusogens and adapter systems thereof and related lipid particles and uses |
| KR20260016952A (ko) | 2023-05-23 | 2026-02-04 | 사나 바이오테크놀로지, 인크. | 탠덤 퓨소젠 및 관련 지질 입자 |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL78703A (en) | 1985-05-10 | 1993-02-21 | Benzon Alfred | Method of producing extracellular enzymes, the enzymes produced thereby and compositions containing them; a hybrid plasmid and a dna fragment comprising dna encoding the enzymes; a microorganism harbouring the plasmid; and a method for removing nucleic acids from biological materials |
| US6534051B1 (en) * | 1992-11-20 | 2003-03-18 | University Of Medicine And Dentistry Of New Jersey | Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins |
| JPH10501403A (ja) * | 1994-03-04 | 1998-02-10 | ユニバーシティ オブ メディシン アンド デンティストリー オブ ニュージャージー | 抗体−エンベロープ融合タンパク質および野生型エンベロープ融合タンパク質を含むレトロウィルスベクターを用いる細胞型特異的遺伝子移入 |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| PL332875A1 (en) | 1996-10-17 | 1999-10-25 | Oxford Biomedica Ltd | Retroviral vectors |
| EP0969876A2 (en) * | 1997-04-17 | 2000-01-12 | Paola Leone | Delivery system for gene therapy to the brain |
| JPH10313865A (ja) * | 1997-05-15 | 1998-12-02 | Deinabetsuku Kenkyusho:Kk | ヒト補体制御因子が呈示されたベクター |
| WO1999013905A1 (en) | 1997-09-18 | 1999-03-25 | The Trustees Of The University Of Pennsylvania | Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery |
| GB9720465D0 (en) | 1997-09-25 | 1997-11-26 | Oxford Biomedica Ltd | Dual-virus vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| ES2373406T3 (es) | 1997-12-22 | 2012-02-03 | Oxford Biomedica (Uk) Limited | Vectores basados en el virus de la anemia infecciosa equina (vaie). |
| JP2003532368A (ja) * | 1998-02-09 | 2003-11-05 | ジェンザイム・コーポレイション | 核酸デリバリービヒクル |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| DE60132436T2 (de) * | 2000-03-30 | 2008-04-17 | Oxford Biomedica (Uk) Ltd. | Retinolsäure-rezeptor beta-2 und gentherapievektoren für die behandlung von neurologischen erkrankungen |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| ATE452972T1 (de) | 2001-05-01 | 2010-01-15 | Ca Nat Research Council | Induzierbares expressionssystem in eukaryotischen zellen |
| CA2464887A1 (en) * | 2001-10-30 | 2003-05-08 | Biogen, Inc. | Methods and compositions for treating parkinson's disease |
| US20040028687A1 (en) | 2002-01-15 | 2004-02-12 | Waelti Ernst Rudolf | Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues |
| AU2003258060B2 (en) | 2002-03-27 | 2007-07-12 | Baylor College Of Medicine | Potent oncolytic herpes simplex virus for cancer therapy |
| ES2627445T3 (es) | 2002-05-01 | 2017-07-28 | Miltenyi Biotec Technology, Inc. | Partículas de vector de lentivirus resistentes a la inactivación por el complemento |
| DE60335672D1 (de) | 2002-05-14 | 2011-02-17 | Merck Sharp & Dohme | Verfahren zur reinigung von adenovirus |
| PL377161A1 (pl) | 2002-11-21 | 2006-01-23 | Pevion Biotech Ltd. | Wysoce efektywne pęcherzyki fuzogenne, sposób ich wytwarzania oraz kompozycje farmaceutyczne zawierające te pęcherzyki |
| WO2006027202A1 (en) | 2004-09-06 | 2006-03-16 | Unite De Recherche En Biotherapie Et Oncologie (Rubio) | Generation of multiparent cell hybrids |
| JP2008518630A (ja) | 2004-11-08 | 2008-06-05 | イェール ユニバーシティ | リボスイッチ、リボスイッチによる、構造を基礎とする化合物設計、ならびにリボスイッチの使用方法およびリボスイッチを伴う組成物 |
| US8034331B2 (en) * | 2005-01-20 | 2011-10-11 | Agency For Science, Technology And Research | Method of delivery of nucleic acids to peripheral neurons |
| PL2002003T3 (pl) * | 2005-05-27 | 2016-06-30 | Ospedale San Raffaele Srl | Wektor genetyczny zawierający mi-RNA |
| WO2007099387A1 (en) | 2006-03-03 | 2007-09-07 | Mymetics Corporation | Virosome-like vesicles comprising gp41-derived antigens |
| WO2008071959A1 (en) * | 2006-12-12 | 2008-06-19 | Oxford Biomedica (Uk) Limited | Lentiviral vectors comprising micrornas |
| US20100040650A1 (en) * | 2008-05-30 | 2010-02-18 | Crowe Jr James E | Virus-Like paramyxovirus particles and vaccines |
| CN102264349A (zh) * | 2008-11-07 | 2011-11-30 | 儿童医院医疗中心 | 用于跨膜药物递送系统的鞘脂激活蛋白c以及相关蛋白和肽促融合性质 |
| US9050269B2 (en) | 2009-03-10 | 2015-06-09 | The Trustees Of The University Of Pennsylvania | Protection of virus particles from phagocytosis by expression of CD47 |
| ES2693167T3 (es) * | 2009-11-13 | 2018-12-07 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Administración directa de proteínas con microvesículas modificadas por ingeniería |
| WO2012156839A2 (en) | 2011-05-19 | 2012-11-22 | Ospedale San Raffaele S.R.L. | New generation of splice-less lentiviral vectors for safer gene therapy applications |
| RU2014100160A (ru) * | 2011-06-10 | 2015-07-20 | Блуберд Байо, Инк. | Векторы генной терапии адренолейкодистрофии и адреномиелонейропатии |
| JP2013034401A (ja) * | 2011-08-04 | 2013-02-21 | Gunma Univ | アストロサイトで遺伝子を発現させるためのベクター |
| DE112012007250B4 (de) | 2012-12-20 | 2024-10-24 | Mitsubishi Electric Corp. | Fahrzeuginterne Vorrichtung und Programm |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| GB201412494D0 (en) | 2014-07-14 | 2014-08-27 | Ospedale San Raffaele And Fond Telethon | Vector production |
| WO2017004381A1 (en) * | 2015-06-30 | 2017-01-05 | St. Jude Children's Research Hospital, Inc. | Method for treating schizophrenia |
| JP7097070B2 (ja) * | 2015-10-01 | 2022-07-07 | ゴレイニ インコーポレイテッド | クロライドチャネルの標的発現及びその使用方法 |
| US11248238B2 (en) * | 2015-10-22 | 2022-02-15 | Juno Therapeutics Gmbh | Methods, kits, agents and apparatuses for transduction |
| US20170112773A1 (en) | 2015-10-23 | 2017-04-27 | Board Of Regents, The University Of Texas System | Plasma membrane vesicles comprising functional transmembrane proteins |
| RU2021102893A (ru) * | 2015-11-05 | 2021-03-03 | Бамбу Терапьютикс, Инк. | Модифицированные гены атаксии фридрейха и векторы для генной терапии |
| US11185555B2 (en) * | 2016-04-11 | 2021-11-30 | Noah James Harrison | Method to kill pathogenic microbes in a patient |
| EP3235908A1 (en) * | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| EP3472318B1 (en) * | 2016-07-08 | 2023-09-06 | Exuma Biotech Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| JP7483373B2 (ja) | 2016-07-29 | 2024-05-15 | ジュノー セラピューティクス インコーポレイテッド | 複製可能ウイルスの存在または非存在を評価するための方法 |
| WO2019077149A1 (en) * | 2017-10-20 | 2019-04-25 | Genethon | USE OF SYNCYTINE FOR TARGETING DRUG AND GENE ADMINISTRATION TO REGENERATE MUSCLE TISSUE |
| WO2019204666A1 (en) * | 2018-04-18 | 2019-10-24 | Oisin Biotechnologies, Inc. | Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease, condition, or disorder associated with a target cell |
| GB201807945D0 (en) * | 2018-05-16 | 2018-06-27 | Ospedale San Raffaele Srl | Vector production |
-
2019
- 2019-11-14 SG SG11202105079QA patent/SG11202105079QA/en unknown
- 2019-11-14 CA CA3120082A patent/CA3120082A1/en active Pending
- 2019-11-14 CN CN201980088528.XA patent/CN113613633A/zh active Pending
- 2019-11-14 JP JP2021526394A patent/JP7676305B2/ja active Active
- 2019-11-14 US US17/293,842 patent/US20220008557A1/en active Pending
- 2019-11-14 KR KR1020217018175A patent/KR20210133948A/ko not_active Ceased
- 2019-11-14 AU AU2019378881A patent/AU2019378881A1/en active Pending
- 2019-11-14 EP EP19817064.9A patent/EP3880179A2/en active Pending
- 2019-11-14 WO PCT/US2019/061424 patent/WO2020102499A2/en not_active Ceased
-
2021
- 2021-05-13 IL IL283179A patent/IL283179A/en unknown
-
2025
- 2025-04-30 JP JP2025075701A patent/JP2025111747A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020102499A5 (https=) | ||
| JP2025111747A5 (https=) | ||
| JP2025066771A (ja) | サプレッサーｔＲＮＡ及びデアミナーゼによる変異のＲＮＡターゲティング | |
| JP6634073B2 (ja) | リソソーム蓄積症処置用のアデノ随伴ウイルスベクター | |
| CN105567735A (zh) | 一种凝血因子基因突变的定点修复载体系统及方法 | |
| US20240108751A1 (en) | Rna-targeting compositions and methods for treating myotonic dystrophy type 1 | |
| US20210054370A1 (en) | Methods and compositions for treating angelman syndrome | |
| WO2017109039A1 (en) | Endothelium-specific nucleic acid regulatory elements and methods and use thereof | |
| EP4590323A2 (en) | Direct reprogramming of human astrocytes to neurons with crispr-based transcriptional activation | |
| CN119013404A (zh) | 用于产生环状rna的载体 | |
| US20240000914A1 (en) | Chicken anemia virus (cav)-based vectors | |
| CN117018231B (zh) | 用于治疗神经病变的基因疗法及其应用 | |
| US20220370638A1 (en) | Compositions and methods for treatment of maple syrup urine disease | |
| WO2021191628A1 (en) | Forskolin-inducible promoters and hypoxia-inducible promoters | |
| KR20230003569A (ko) | Cdkl5 결핍 장애 (cdd)의 치료에 유용한 조성물 | |
| US20220193265A1 (en) | Methods and compositions for reprogramming müller glia | |
| US20250325706A1 (en) | Linker peptide, fviii protein or variant thereof containing linker peptide, and use thereof | |
| CN113913463B (zh) | 抑制sost基因表达的重组质粒及其骨靶向重组腺相关病毒与应用 | |
| WO2023235888A2 (en) | COMPOSITIONS AND METHODS FOR CpG DEPLETION | |
| WO2022221278A1 (en) | Compositions and methods comprising hybrid promoters | |
| US20230167458A1 (en) | Forskolin-inducible promoters and hypoxia-inducible promoters | |
| Owen IV et al. | Approaches and limitations to gene therapy for mitochondrial diseases | |
| US20240229096A1 (en) | Recombinant cell and method for producing endogenous polypeptide | |
| CN120098148B (zh) | 一种工程化巨噬细胞制备及抗纤维化的应用 | |
| US20250302992A1 (en) | Polycistronic Expression of Gut Peptides |